Technical Analysis for LRMR - Larimar Therapeutics, Inc.

Grade Last Price % Change Price Change
D 6.08 -4.70% -0.30
LRMR closed down 4.7 percent on Wednesday, November 20, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Slingshot Bearish Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -4.70%
Wide Bands Range Expansion -4.70%
Lower Bollinger Band Touch Weakness -4.70%
Oversold Stochastic Weakness -4.70%

   Recent Intraday Alerts

Alert Time
Fell Below Lower Bollinger Band about 17 hours ago
Down 5% about 18 hours ago
Lower Bollinger Band Support about 21 hours ago
60 Minute Opening Range Breakdown about 22 hours ago
Down 3% about 22 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Drug Discovery Rare Diseases Genetic Diseases Progressive Clinical Pharmacology Fusion Protein Ataxia Friedreich's Ataxia Trinucleotide Repeat Disorders

Is LRMR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.68
52 Week Low 3.19
Average Volume 747,655
200-Day Moving Average 8.13
50-Day Moving Average 7.29
20-Day Moving Average 7.82
10-Day Moving Average 7.72
Average True Range 0.67
RSI (14) 36.31
ADX 25.71
+DI 21.82
-DI 32.49
Chandelier Exit (Long, 3 ATRs) 7.49
Chandelier Exit (Short, 3 ATRs) 7.93
Upper Bollinger Bands 9.66
Lower Bollinger Band 5.99
Percent B (%b) 0.02
BandWidth 46.89
MACD Line -0.23
MACD Signal Line 0.07
MACD Histogram -0.3021
Fundamentals Value
Market Cap 266.95 Million
Num Shares 43.9 Million
EPS -0.60
Price-to-Earnings (P/E) Ratio -10.13
Price-to-Sales 0.00
Price-to-Book 3.68
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.07
Resistance 3 (R3) 7.13 6.87 6.91
Resistance 2 (R2) 6.87 6.61 6.84 6.85
Resistance 1 (R1) 6.47 6.46 6.34 6.41 6.79
Pivot Point 6.21 6.21 6.14 6.18 6.21
Support 1 (S1) 5.81 5.95 5.68 5.75 5.37
Support 2 (S2) 5.55 5.80 5.52 5.31
Support 3 (S3) 5.15 5.55 5.26
Support 4 (S4) 5.09